Cargando…

Targeting metabolism to treat multiple sclerosis

Detalles Bibliográficos
Autor principal:	Bhargava, Pavan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2020
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996022/ https://www.ncbi.nlm.nih.gov/pubmed/32985474 http://dx.doi.org/10.4103/1673-5374.293143

Ejemplares similares

Perspectives on neuroreparative therapies for treating multiple sclerosis
por: Xiao, Junhua
Publicado: (2015)

Metabolic checkpoints in neurodegenerative T helper 17 (T(H)17) and neuroregenerative regulatory T (T(reg)) cells as new therapeutic targets for multiple sclerosis
por: Shen, Hongxing, et al.
Publicado: (2019)

Pharmacological interventions targeting nuclear factor-kappa B signaling in multiple sclerosis
por: De Kleijn, Kim M. A., et al.
Publicado: (2021)

Altered tryptophan metabolism is associated with pediatric multiple sclerosis risk and course
por: Nourbakhsh, Bardia, et al.
Publicado: (2018)

Drug repurposing for neuroregeneration in multiple sclerosis
por: Küry, Patrick, et al.
Publicado: (2018)

Multiple sclerosis drug repurposing for neuroregeneration
por: Göttle, Peter, et al.
Publicado: (2023)

Programmed cell death and natural killer cells in multiple sclerosis: new potential therapeutic targets?
por: Macchi, Beatrice, et al.
Publicado: (2016)

On the road to new treatments for multiple sclerosis: targeting dendritic cell migration into the central nervous system
por: Meena, Megha, et al.
Publicado: (2019)

Tremor in Multiple Sclerosis—An Overview and Future Perspectives
por: Makhoul, Karim, et al.
Publicado: (2020)

Multiple Sclerosis: Overview of Disease-Modifying Agents
por: Finkelsztejn, Alessandro
Publicado: (2014)

Immunological role of sulfatide in the pathogenesis of multiple sclerosis
por: Hamatani, Mio, et al.
Publicado: (2023)

Ependymal cells and multiple sclerosis: proposing a relationship
por: Hatrock, Dale, et al.
Publicado: (2019)

Orexin/hypocretinin in multiple sclerosis and experimental autoimmune encephalomyelitis
por: Pallais, Jean Pierre, et al.
Publicado: (2019)

Glucose metabolism in amyotrophic lateral sclerosis: it is bitter-sweet
por: Lerskiatiphanich, Titaya, et al.
Publicado: (2022)

Myelin positron emission tomography (PET) imaging in multiple sclerosis
por: de Paula Faria, Daniele
Publicado: (2020)

The Importance of the Cognitive Aspects of Vocational Rehabilitation for Individuals With Multiple Sclerosis
por: Kennedy, Winston, et al.
Publicado: (2020)

Focusing on caveolin-1 in CNS autoimmune disease: multiple sclerosis
por: Wu, Hao, et al.
Publicado: (2016)

Galectin-3 prospects as a therapeutic agent for multiple sclerosis
por: Thomas, Laura, et al.
Publicado: (2019)

Brain network correlates of epilepsy occurrence in multiple sclerosis and neuroinflammation
por: Ciolac, Dumitru, et al.
Publicado: (2022)

Trans-synaptic degeneration as a mechanism of neurodegeneration in multiple sclerosis
por: Murphy, Olwen C., et al.
Publicado: (2023)

Understanding metabolic flexibility: a potential key to unlocking metabolic therapies in amyotrophic lateral sclerosis?
por: Allen, Scott P.
Publicado: (2020)

Environmental enrichment as a promising strategy for aiding multiple sclerosis treatment
por: Silva, Berenice Anabel, et al.
Publicado: (2020)

Role of CD20(+) T cells in multiple sclerosis: implications for treatment with ocrelizumab
por: Gingele, Stefan, et al.
Publicado: (2019)

Biochemical indicators for neuronal regeneration during intrathecal triamcinolone application in multiple sclerosis
por: Müller, Thomas, et al.
Publicado: (2015)

Multiple sclerosis: why we should focus on both sides of the (auto) antibody
por: den Dunnen, Jeroen, et al.
Publicado: (2021)

Neuronal and endothelial transglutaminase-2 expression in experimental autoimmune encephalomyelitis and multiple sclerosis
por: Pearse, Damien D., et al.
Publicado: (2021)

Synaptic pathology in multiple sclerosis: a role for Nogo-A signaling in astrocytes?
por: Espírito-Santo, Sheila, et al.
Publicado: (2022)

Emerging role of neuregulin-1beta1 in pathogenesis and progression of multiple sclerosis
por: Ziaee, Seyyed Mohyeddin, et al.
Publicado: (2022)

Targeting Metabolism, Insulin Resistance, and Diabetes to Treat Nonalcoholic Steatohepatitis
por: Finck, Brian N.
Publicado: (2018)

Can Blood Gene Expression Predict Which Patients with Multiple Sclerosis Will Respond to Interferon?
por: Kaminski, Naftali, et al.
Publicado: (2005)

Multiple sclerosis and neuromyelitis optica spectrum disorders: some similarities in two distinct diseases
por: Yokote, Hiroaki, et al.
Publicado: (2016)

Neuronal gene transcription modulates demyelination and remyelination in a mouse model of multiple sclerosis
por: Anastasiadou, Sofia, et al.
Publicado: (2015)

Chemotactic signaling and beyond: link between interleukin-16 and axonal degeneration in multiple sclerosis
por: Skundric, Dusanka S.
Publicado: (2015)

Finding a way to preserve mitochondria: new pathogenic pathways in experimental multiple sclerosis
por: Mancini, Andrea, et al.
Publicado: (2019)

New ex vivo demyelination/remyelination models to defeat multiple sclerosis and neuromyelitis optica
por: Liu, Yiting
Publicado: (2019)

Pannexin 1-based channels activity as a novel regulator of multiple sclerosis progression
por: Ortiz, Fernando C., et al.
Publicado: (2019)

When neurologist and patient disagree on reasonable risk: new challenges in prescribing for patients with multiple sclerosis
por: Kachuck, Norman J
Publicado: (2011)

Soluble interleukin 23 receptor gene therapy with adeno-associated vectors for the treatment of multiple sclerosis
por: Edo, Ángel, et al.
Publicado: (2017)

Multiple Rediscoveries and Misconceptions; the Yeast Metabolic Oscillation
por: Murray, Douglas B, et al.
Publicado: (2021)

Mesenchymal stem cells require the peripheral immune system for immunomodulating effects in animal models of multiple sclerosis
por: Salinas Tejedor, Laura, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_60nfg73che28k519aki3mkam3l